Elevai Labs, Inc. Common Stock Cash Flow Conversion Efficiency
Elevai Labs, Inc. Common Stock cash flow conversion efficiency. Based on the latest financial reports, Elevai Labs, Inc. Common Stock (ELAB) has a cash flow conversion efficiency ratio of -0.119x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.99 Million) by net assets ($16.74 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Elevai Labs, Inc. Common Stock (2020–2025)
Cash flow conversion efficiency of Elevai Labs, Inc. Common Stock from 2020 to 2025. This chart illustrates how Elevai Labs, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. View today's stock price for Elevai Labs, Inc. Common Stock for real-time trading data and today's change.
Elevai Labs, Inc. Common Stock Cash Flow Conversion Ratio Explained
Elevai Labs, Inc. Common Stock cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Elevai Labs, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Elevai Labs, Inc. Common Stock ranked by their cash flow conversion efficiency. Also see ELAB company net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Triangle Energy (Global) Ltd
AU:TEG
|
3.581x |
|
Lazydays Holdings Inc
NASDAQ:GORV
|
0.889x |
|
BrightBid Group AB (publ)
ST:PERP-B
|
-0.071x |
|
Yangaroo Inc
V:YOO
|
0.540x |
|
BioSenic S.A.
BR:BIOS
|
0.059x |
|
CQS Natural Resources Growth and Income plc
LSE:CYN
|
0.014x |
|
TNL Mediagene Ordinary Shares
NASDAQ:TNMG
|
-3.332x |
|
Avrupa Minerals Ltd
V:AVU
|
-0.155x |
Annual Cash Flow Conversion Efficiency for Elevai Labs, Inc. Common Stock (2020–2025)
The table below shows the annual cash flow conversion efficiency of Elevai Labs, Inc. Common Stock from 2020 to 2025. Review Elevai Labs, Inc. Common Stock free cash flow to debt ratio to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $7.84 Million | $-5.93 Million | -0.757x | +8.11% |
| 2024-12-31 | $6.66 Million | $-5.49 Million | -0.824x | +30.80% |
| 2023-12-31 | $3.83 Million | $-4.56 Million | -1.191x | +15.06% |
| 2022-12-31 | $1.13 Million | $-1.59 Million | -1.402x | +4.42% |
| 2021-12-31 | $450.63K | $-660.93K | -1.467x | -115.93% |
| 2020-12-31 | $-23.59K | $-217.16K | 9.206x | -- |
About Elevai Labs, Inc. Common Stock
PMGC Holdings Inc., a biopharmaceutical company, focuses on the development and acquisition of aesthetic medicines and therapeutic products. It operates through three segments: corporate, treasury and biosciences; IT packaging solutions; and precision engineering and machining. The company's lead product includes EL-22, a first-in-class engineered probiotic approach to address obesity's pressing … Read more